A phase 3 multicenter, open ‐label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting

CONCLUSIONSA single 3‐mg dose of NG was effective in treating moderate, symptomatic, hypoglycemic events in children and adolescents with T1D in a real‐world setting. It was easy to use and reasonably well tolerated. NG shows promise as an effective, needle‐free, and user‐friendly alternative to injectable glucagon.

Source: Pediatric Diabetes - March 1, 2018 Category: Endocrinology Authors: Larry C. Deeb, H élène Dulude, Cristina B. Guzman, Shuyu Zhang, Barry J. Reiner, Claude A. Piché, Sheetal Pradhan, Xiaotian Michelle Zhang Tags: ORIGINAL ARTICLE Source Type: research